

Format for ANSWERING REVIEWERS



December 7, 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 6330-review.doc).

Title: Incretin based therapies-a novel treatment approach for non-alcoholic fatty liver disease

Author: Kristina Blaslov, Tomislav Bulum, Karin Zibar, Lea Duvnjak

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 6330

The manuscript has been improved according to the suggestions of reviewers:

1 Format of the references has been updated. The references that were equal were deleted. Since the language evaluation of our manuscript reached grade A from all the reviewers, according to the 'The Revision Policies of BPG for TOPIC HIGHLIGHT', we choose our manuscript not to be edited by English language Editing Company.

2 Revision has been made according to the suggestions of the reviewer

(1) There are certain grammatical errors. These are as follows:

1. In the abstract, 6th line -----enhances glucose-stimulated----
2. In the abstract, line 7 to 10, Glucagon-like peptide (GLP-1) is the most important incretin . Its receptor agonist and inhibitors of dipeptidyl peptidase-4 are used in the treatment of Diabetes mellitus.
3. In the abstract, line 16 and 17, ----- further studies are needed to assess the long-term effects of incretin based therapies on NAFLD.
4. In the Core Tip, line 5 -----which
5. In the Introduction, line 9, ----- diabetic hepatitis -----
6. Last sentence of the paragraph - The pathogenesis and metabolic changes in NAFLD: ----- the presence of insulin resistance -
7. In the paragraph of Incretin based therapies - indirect action, the sentence before the last one: -----serving as local endogenous---
8. In the paragraph of Incretin based therapies - a direct action: endoplasmic stress is a major player in the progression of fatty liver.

We acknowledge the reviewer for all the comments on grammatical errors and corrected them as suggested.

(2) "In the introduction, the impact of the studies based on metformin and pioglitazone should need to be more detailed, due to the amount of information in the literature, that is analyzed in a recent meta-analysis (Musso G. A Meta-Analysis of randomized trials for the treatment of NAFLD Hepatology 2010;52:79-104). I think, so, that the clinical trial by Sanyal et al (Sanyal A. N Engl J Med 2010;362:1675-85) about vit E and pioglitazones should be commented. Furthermore, the recommendation for the use of thiazolidindiones in a recent American Guideline should be in this

paragraph (AASLD Guidelines: Chalasani N. Hepatology 2012; 2005-2023)".

We acknowledge the Reviewer for the comment. We expanded the Introduction as suggested starting with sentence: "A recent meta-analysis by Musso et al..."

"The incretin analogues have been approved as an option of the treatment of tipo II Diabetes. Only type II diabetic patients with NAFLD/NASH have been studied with incretin analogues or DPP-4 inhibitors, therefore, the conclusions of this review only can be applied to type II diabetic patients suffering for NASH, and not for the nondiabetic-NAFLD patients"

We acknowledge the Reviewer for the comment, we finished our Discussion emphasising the suggested limitation.

"There some mistakes in the references a. 44: Is it an abstract? b. 52: I don't understand this reference c. Numbers 57 and 67 are the same reference"

We acknowledge the Reviewer for the comment. Reference 44. was an Abstract but since there is a full text article it has been replaced (Ref 49). Reference 52. was replaced with more accurate one (Ref 50). The repeted references were deleted.

3 References and typesetting were corrected

Thank you again for concideration of publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Kristina Blaslov, MD

Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur,
University of Zagreb, School of Medicine,

Dugi dol 4a

10000 Zagreb, Croatia

Fax: +385-1-235-3829

E-mail: kblaslov@gmail.com

A handwritten signature in blue ink, appearing to read 'K. Blaslov', is enclosed in a light green rectangular box.